Lv12
60 积分 2021-08-18 加入
Emerging insights into natural killer cells in human peripheral tissues
1天前
已完结
A novel triple-knockout allogeneic BCMA CAR T cell therapy (CT0590) in multiple myeloma: preclinical and phase I study
14天前
已完结
How I treat HLH-like toxicities after immune effector cell therapy
20天前
已完结
Type I interferon inhibitor anifrolumab in active systemic lupus erythematosus (TULIP-1): a randomised, controlled, phase 3 trial
2个月前
已完结
Teclistamab plus Daratumumab in Relapsed or Refractory Multiple Myeloma
2个月前
已完结
A practical Bayesian design to identify the maximum tolerated dose contour for drug combination trials
3个月前
已完结
Bayesian optimal interval design for dose finding in drug-combination trials
3个月前
已完结
Glofitamab plus gemcitabine and oxaliplatin (GemOx) versus rituximab-GemOx for relapsed or refractory diffuse large B-cell lymphoma (STARGLO): a global phase 3, randomised, open-label trial
4个月前
已完结
Glofitamab plus gemcitabine and oxaliplatin (GemOx) versus rituximab-GemOx for relapsed or refractory diffuse large B-cell lymphoma (STARGLO): a global phase 3, randomised, open-label trial
4个月前
已完结
Preclinical development and a case report of a nanobody-based CLDN18.2 CAR-T IMC002 with reduced on-target off-tumor toxicity
5个月前
已完结
皖公网安备34019202002308
